Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris’ Cebranopadol Shows Positive Phase 3 Results in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Reports Low Abusability for Cebranopadol Pain Therapy
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Presents Positive ALLEVIATE-1 Trial Data for Cebranopadol in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Expands Global ADHD Drug Availability with New Approvals
Details : Quillivant (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, which is indicated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Product Name : Quillivant XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Starts ALLEVIATE-1 and 2 Trials of Cebranopadol for Pain Treatment
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Gets FDA Approval for ONYDA XR, First Liquid ADHD Medication
Details : FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Product Name : Onyda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Details : Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their ...
Product Name : Dyanavel XR
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Quillivant XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Product Name : TRN-228
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable